Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4914453_CN14453_0